Cellectis Pivots to Gene Editing in Major Overhaul
Cellectis (NASDAQ: CLLS) pivots to in vivo gene editing, extending cash runway to H2 2028. Read pipeline updates on .HEAL-101 & .HEAL-201.
Share
Why It Matters
Cellectis changed its focus to a new type of gene therapy work. This move gives the company more time and money to finish testing.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.